Sitravatinib 5 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
Search Results
Azoramide 100 mg | 99.71%
TargetMol
Azoramide, a small-molecule modulator, has the antidiabetic activity of unfolded protein response.
More Information Supplier PageAzoramide
Azoramide 50 mg | 99.71%
TargetMol
Azoramide, a small-molecule modulator, has the antidiabetic activity of unfolded protein response.
More Information Supplier PageAzoramide
Azoramide 10 mg | 99.71%
TargetMol
Azoramide, a small-molecule modulator, has the antidiabetic activity of unfolded protein response.
More Information Supplier PageAzoramide
(+)-Isocorydine hydrochloride 100 mg | 99.72%
TargetMol
(+)-Isocorydine hydrochloride
(+)-Isocorydine hydrochloride 10 mg | 99.72%
TargetMol
(+)-Isocorydine hydrochloride
Sitravatinib 25 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
Sitravatinib 50 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
PHTPP 100 mg | 99.72%
TargetMol
PHTPP
PHTPP 25 mg | 99.72%
TargetMol
PHTPP